A review of rizatriptan, a quick and consistent 5-HT_1B/1D agonist for the acute treatment of migraine

Bibliography

• LIPTON RB, SILBERSTEIN SD, STEWART WF: An update on the epidemiology of migraine. Headache (1994) 34:319–328.
   PubMed Web of Science ®Google Scholar
• HEADACHE CLASSIFICATION SUBCOMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: The International Classification of Headache Disorders (2nd edn). Cephalalgia (2004) 24\(Suppl. 1):1–160.
   Google Scholar
• ••The new operational criteria for the diagnosis of headache disorders.
   Google Scholar
• GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine — current understanding and treatment.N Engl.' Merl (2002) 346:257–270.
   PubMed Web of Science ®Google Scholar
• TFELT-HANSEN P, SAXENA PR, DAHLOF C et al.: Ergotamine in the acute treatment of migraine — a review and European consensus. Brain (2000) 123:9–18.
   PubMed Web of Science ®Google Scholar
• ••The best review on the current role ofergotarnine in the treatment of migraine.
   Google Scholar
• FERRARI MD, ROON KI, LIPTON RB, GOADSBY PJ: Triptans (serotonin, 5-FITIB/ID agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet (2001) 358: 1668–1675.
   Google Scholar
• ••An independent meta-analysis of placebo-Acontrolled clinical trials with triptans.
   Google Scholar
• FERRARI MD, GOADSBY PJ, ROON KI, LIPTON RB: Triptans (serotonin,
   Google Scholar
• HTIB,ID agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia (2002) 22:633–658.
   PubMedGoogle Scholar
• ••Detailed data of the above meta-analysis.
   Google Scholar
• DAHLOF C, LINES C: Rizatriptan: a new5-HT mim receptor agonist for the treatmentof migraine. Expert Opin. Investig. Drugs (1999) 8:671–685.
   PubMedGoogle Scholar
• TFELT-HANSEN P, DE VRIES P,SAXENA PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs (2000) 60:1259–1287.
   PubMed Web of Science ®Google Scholar
• DOOLEY M, FAULDS D: Rizatriptan. A review of its efficacy in the management of migraine. Drugs (1999) 58:699–723.
   PubMed Web of Science ®Google Scholar
• LONGMORE J, RAZZAQUE Z, SHAW D et al.: Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br: J. Clin. Pharmacol (1998) 46:577–582.
   PubMed Web of Science ®Google Scholar
• LONGMORE J, BOULANGER CM, DESTA B, HILL RG, SCHOFIELD WN, TAYLOR AA: 5-HTID receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br: J. Clin. Pharmacol (1996) 42:431–441.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, HILL RG, SHEPHEARD SL, HARGREAVES RJ: The anti-migraine 5-HT (1B71D) agonist rizatriptan inhibits neurogenic dural vasodilation in anesthetized guinea-pigs. Br: J. Pharmacol (2001) 133:1029–1034.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, SHEPHEARD SL, HILL RG, HARGREAVES RJ:The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur: Pharmacol (1997) 328:37–40.
   PubMedGoogle Scholar
• CUMBERBATCH MJ, HILL RG, SHEPHEARD SL, HARGREAVES R: Rizatriptan has central antinociceptive effects against durally evoked responses. Eur. Pharmacol (1997) 328:49–54.
   Google Scholar
• DAHLOF C, RAPOPORT AM, SHEFTELL FD, LINES C:ARizatriptan in the treatment of migraine. Drug Ther. (1999) 21:1823–1836.
   Google Scholar
• WELLINGTON K, PLOSKER GL: Rizatriptan. An update of its use in the management of migraine. Drugs (2002) 62:1539–1754.
   PubMedGoogle Scholar
• GOLDBERG MR, SCIBERRAS D, DE SMET M et al.: Influence of P-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-11T1st1p agonist: differential effects of propranolol, nadolol and metoprolol. Br. J. Pharmacol (2001) 52:69–76.
   Google Scholar
• TFELT-HANSEN P, SEIDELIN K, STEPANAVAGE M, LINES C:The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects. Br: J. Chu. Pharmacol (2002) 54:38–44.
   PubMed Web of Science ®Google Scholar
• SHADLE CR, LIU G, GOLDBERG MR: A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers. Chu. Pharmacol (2000) 40:309–315.
   Google Scholar
• GOLBERG MR, LOWRY RC,MUSSON DG et al:Lack of pharmacokinetic andpharmacodynamic interaction between rizatriptan and paroxetine.J. Chu. Pharmacol (1999) 39:192–199.
   Google Scholar
• TEALL J, TUCHMAN M, CUTLER N et al., ON BEHALF OF THE RIZATRIPTAN 022 STUDY GROUP: Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence: a placebo-controlled, outpatient study. Headache (1998) 38:281–287.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN J, RYAN R, JIANG K et al.,ON BEHALF OF THE RIZATRIPTAN PROTOCOL 046 STUDY GROUP: Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache (1998) 38:737–747.
   PubMed Web of Science ®Google Scholar
• GIJSMAN H, KRAMER MS, SARGENT J et al.: Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia (1997) 17:647–651.
   PubMed Web of Science ®Google Scholar
• TFELT-HANSEN P, TEALL J, RODRIGUEZ F et al., ON BEHALF OF THE RIZATRIPTAN 030 STUDY GROUP: Oral rizatriptan versus oral sumatriptan: a direct comparison study in the acute treatment of migraine. Headache (1998) 38:748–755.
   PubMed Web of Science ®Google Scholar
• VISSER WH, TERWINDT GM, REINES SA, JIANG K, LINES CR, FERRARI MD: Rizatriptan versus sumatriptan in the acute treatment of migraine. Arch. Neurol (1996) 53:1132–1137.
   PubMed Web of Science ®Google Scholar
• LINES C, VISSER H, VANDORMAEL K, REINES SA: Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Headache (1997) 37:319–320.
   Google Scholar
• KRAMER MS, MATZURA-WOLFE D, POLIS A et al., ON BEHALF OF THE RIZATRIPTAN MULTIPLE ATTACK STUDY GROUP: A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology (1998) 51:773–781.
   PubMed Web of Science ®Google Scholar
• ••Probably the best trial for any triptananalysing the consistency of rizatriptan versus placebo.
   Google Scholar
• LIPTON RB, PASCUAL J, GOADSBY PJ et al.: Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache (2001) 41:754–763.
   PubMed Web of Science ®Google Scholar
• BUSSONE G, D'AMICO D, MCCARROLL KA, GERTH W, LINES CR: Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. Ear: Neurol (2002) 48:172–177.
   PubMedGoogle Scholar
• ADELMAN JU, LIPTON RB,FERRARI MD et al.: Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology (2001) 57: 1377–1383.
   Google Scholar
• •Specific analysis demonstrating some superiority of rizatriptan over other triptans in some demanding efficacy measures.
   Google Scholar
• BOMHOF M, PAZ J, LEGG N,ALLEN C, VANDORMAEL K, PATEL K, AND THE RIZATRIPTAN-NARATRIPTAN STUDY GROUP: Comparison of rizatriptan 10 mg versus naratriptan 2,5 mg in migraine. Eur: Neurol (1999) 42:173–179.
   PubMed Web of Science ®Google Scholar
• •One of the few trials in the literature comparing two triptans other than sumatriptan.
   Google Scholar
• PASCUAL J, VEGA P, DIENER HC,ALLEN C, VRIJENS F, PATEL K, ON BEHALF OF THE RIZATRIPTAN-ZOLMITRIPTAN STUDY GROUP: Comparison of rizatriptan 10 mg versus zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia (2000) 20:455–461.
   PubMed Web of Science ®Google Scholar
• •The comparative trial against zolrnitriptan. Again one of the few comparative trials involving triptans other than sumatriptan.
   Google Scholar
• BLOCK GA, GOLDSTEIN J, POLIS A,REINES SA, SMITH ME, ON BEHALF OF THE RIZATRIPTAN MULTICENTER GROUP:Efficacy and safety of rizatriptan versus standard care during long-term treatment of migraine. Headache (1998) 38:764–771.
   PubMed Web of Science ®Google Scholar
• •The necessary long-term clinical trial with rizatriptan versus standard care, which in this case, was mostly oral sumatriptan.
   Google Scholar
• AHRENS SP, FARMAER MV,WILLIAMS DL et al: Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia (1999) 19:525–530.
   PubMed Web of Science ®Google Scholar
• PASCUAL J, BUSSONE G,HERNANDEZ JF, ALLEN C, VRIJENS F, PATEL K, ON BEHALF OF THE RIZATRIPTAN-SUMATRIPTAN PREFERENCE STUDY GROUP: Comparison of preference for rizatriptan 10 mg wafer versus sumatriptan 50 mg tablet in migraine. Eur. Neurel. (2001) 45:275–283.
   PubMed Web of Science ®Google Scholar
• LODER E, BRANDES JL,SILBERSTEIN SD et al., ON BEHALF OF THE RIZATRIPTAN PROTOCOL 060 STUDY GROUP: Preference comparison of rizatriptan ODT 10 mg and sumatriptan 50 mg tablet in migraine. Headache (2001) 41:745–753.
   PubMed Web of Science ®Google Scholar
• ADELMAN JU, MANNIX LK, VON SEGGERN RL: Rizatriptan tablet versus wafer: patient preference. Headache (2000) 40:371–372.
   PubMed Web of Science ®Google Scholar
• GERTH WC, MACCAROLL KA, SANTANELLO NC: Patient satisfaction with rizatriptan versus other triptans: direct head-to-head comparisons.AInt. J. Clin. Pratt (2001) 55:552–556.
   PubMedGoogle Scholar
• CHRISTIE S, GOBEL H, MATEOS V et al.: Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.Eur. Neural. (2003) 49:20–29.
   PubMed Web of Science ®Google Scholar
• BELSEY J: Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management.Clin. Res. (2001) 4:105–125.
   Google Scholar
• LIPTON RB, STEWART WF: Acute migraine therapy. Do doctors understand what patients with migraine want from therapy? Headache (1999) 35:601–606.
   Google Scholar
• DAHLOF CGH, LIPTON RB, MACCARROLL KA, KRAMER MS, LINES CR, FERRARI MD: Within-patient consistency of response of rizatriptan for treating migraine. Neurology (2000) 55: 1511–1516.
   Google Scholar
• PASCUAL J, FITE B, LOPEZ GIL A: Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache (2002) 42:93–98.
   PubMed Web of Science ®Google Scholar
• LEIRA R, DUALDE E, DEL BARRIO H, MACHUCA M, LOPEZ-GIL A, SPANISH GROUP FOR THE STUDY OF TRIPTAN CONSUMPTION IN COMMUNITY PHARMACIES: Almotriptan versus rizatriptan in patients with migraine in Spain. Headache (2003) 43:734–741.
   PubMed Web of Science ®Google Scholar